American Cancer Society, Atlanta, Georgia, USA.
JAMA. 2011 Dec 14;306(22):2495-9. doi: 10.1001/jama.2011.1800.
Guidelines for cancer screening written by different organizations often differ, even when they are based on the same evidence. Those dissimilarities can create confusion among health care professionals, the general public, and policy makers. The Institute of Medicine (IOM) recently released 2 reports to establish new standards for developing more trustworthy clinical practice guidelines and conducting systematic evidence reviews that serve as their basis. Because the American Cancer Society (ACS) is an important source of guidance about cancer screening for both health care practitioners and the general public, it has revised its methods to create a more transparent, consistent, and rigorous process for developing and communicating guidelines. The new ACS methods align with the IOM principles for trustworthy clinical guideline development by creating a single generalist group for writing the guidelines, commissioning independent systematic evidence reviews, and clearly articulating the benefits, limitations, and harms associated with a screening test. This new process should ensure that ACS cancer screening guidelines will continue to be a trustworthy source of information for both health care practitioners and the general public to guide clinical practice, personal choice, and public policy about cancer screening.
不同组织撰写的癌症筛查指南常常存在差异，即使它们基于相同的证据也是如此。这些差异可能会导致医疗保健专业人员、公众和政策制定者感到困惑。医学研究所（IOM）最近发布了 2 份报告，为制定更值得信赖的临床实践指南和进行作为其基础的系统证据审查建立了新标准。由于美国癌症协会（ACS）是医疗保健从业者和公众获取癌症筛查指导的重要来源，因此它已经修订了其方法，为制定和传播指南创建了一个更加透明、一致和严格的流程。新的 ACS 方法符合 IOM 值得信赖的临床指南制定原则，为撰写指南创建了一个单一的通才小组，委托进行独立的系统证据审查，并明确阐述与筛查测试相关的益处、局限性和危害。这个新流程应该确保 ACS 的癌症筛查指南将继续成为医疗保健从业者和公众的可靠信息来源，以指导癌症筛查的临床实践、个人选择和公共政策。
